Asset Details
Do you wish to reserve the book?
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Do you wish to request the book?
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
2019
Overview
Aprocitentan is an orally active, dual endothelin (ET) receptor antagonist developed for the treatment of hypertension in which, despite available treatments, a medical need exists for drugs with a new mechanism of action.
In this study, the single- and multiple-dose tolerability, safety, pharmacokinetics (PK), and pharmacodynamics of up to 600 mg (single doses) and 100 mg once a day (qd; multiple doses) of aprocitentan were investigated in healthy male and female subjects. The effect of age on the tolerability and PK parameters was investigated at a dose of 100 mg qd.
Aprocitentan was well tolerated across all doses. No serious adverse events (AEs) occurred. The most frequently reported AE was headache. Small increases in body weight were recorded in subjects receiving 100 mg qd. Plasma concentration-time profiles of aprocitentan were similar after single- and multiple-dose administration, and support a qd dosing regimen based on a half-life of 44 hours. After multiple doses, PK was dose proportional. Accumulation at steady state, reached by Day 8, was 3-fold. Only minor differences in exposure between healthy females and males, healthy elderly and adult subjects, and fed and fasted conditions were observed. Plasma ET-1 concentrations, reflecting ET
receptor antagonism, significantly increased with doses ≥25 mg. Time-matched analysis of electrocardiogram (ECG) parameters did not suggest drug-induced ECG effects. Exposure-response analysis indicated no QTc prolongations at plasma levels up to 10 µg/mL.
Aprocitentan was well tolerated in healthy subjects with a PK profile favorable for qd dosing.
Publisher
Dove Medical Press Limited,Taylor & Francis Ltd,Dove Medical Press
Subject
/ Adult
/ Aged
/ Analysis
/ Diabetes
/ Dosage
/ Dose-Response Relationship, Drug
/ Drug Administration Schedule
/ Drugs
/ EKG
/ endothelin receptor antagonist
/ Endothelin Receptor Antagonists - administration & dosage
/ Endothelin Receptor Antagonists - adverse effects
/ Endothelin Receptor Antagonists - blood
/ Endothelin Receptor Antagonists - pharmacokinetics
/ Exposure
/ Female
/ Females
/ Headache
/ Humans
/ Male
/ Males
/ Peptides
/ Pyrimidines - administration & dosage
/ Pyrimidines - adverse effects
/ Pyrimidines - pharmacokinetics
/ Receptors, Endothelin - metabolism
/ Safety
/ Sulfonamides - administration & dosage
/ Sulfonamides - adverse effects
/ Sulfonamides - pharmacokinetics
/ Time
